Showing results (1771-1780 of 5,146) with videos related to

Sort By:
Pageof 515
Multiple Sclerosis and Related Disorders|December 16, 2021
Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and ageDejan Jakimovski, Katelyn S Kavak, Caila B Vaughn, et al.
Multiple Sclerosis and Related Disorders|December 16, 2021
Blood lactate concentrations during rest and exercise in people with Multiple Sclerosis: A systematic review and meta-analysisLuke Cerexhe, Chris Easton, Eilidh Macdonald, et al.
Multiple Sclerosis and Related Disorders|December 17, 2021
Implementation study of the 2021 German guideline for diagnosis and treatment of multiple sclerosisC Mokry, C Warnke, K Gehring, et al.
Multiple Sclerosis and Related Disorders|December 19, 2021
A much needed metric: Defining reliable and statistically meaningful change of the oral version Symbol Digit Modalities Test (SDMT)L B Strober, J M Bruce, P A Arnett, et al.
Multiple Sclerosis and Related Disorders|January 15, 2022
Pediatric anti-N-methyl-D-aspartate receptor encephalitis with MOG-Ab co-existence: Relapse propensity and treatabilityZhang Weihua, Gong Shuai, Ren Changhong, et al.
Multiple Sclerosis and Related Disorders|January 16, 2022
Comparing diagnostic criteria for the diagnosis of neurocognitive disorders in multiple sclerosisLaura M Hancock, Bruce Hermann, Menno M Schoonheim, et al.
Multiple Sclerosis and Related Disorders|January 17, 2022
Incidence and risk factors for venous thromboembolism during an acute attack in patients with neuromyelitis optica spectrum disordersJuyuan Pan, Ruofan Zhu, Jie Lin, et al.
Multiple Sclerosis and Related Disorders|January 17, 2022
OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MSJohn J Chen, Elias S Sotirchos, Amanda D Henderson, et al.
Multiple Sclerosis and Related Disorders|January 20, 2022
No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHSLana Zhovtis Ryerson, Robert T Naismith, Lauren B Krupp, et al.
Multiple Sclerosis and Related Disorders|February 26, 2021
Insights into the role of B cells in the cortical pathology of Multiple sclerosis: evidence from animal models and patientsBerenice Anabel Silva, Esteban Miglietta, Carina Cintia Ferrari
Pageof 515